StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.71−2.74 (-2.55%)

Close on Nov 17, 2026Market cap $181.19BP/E 33.7Yield 2.29%

Abbott Laboratories total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Abbott Laboratories's total debt was $32.61B at Jun 30, 2026. For fiscal 2025 it was $12.93B, down 8.5% from the year before. Over ten years it grew 3.7% a year on average. The highest annual figure on record is $27.92B in fiscal 2017.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$12.93B-8.5%
FY2024Dec 31, 2024$14.13B-3.8%
FY2023Dec 31, 2023$14.68B-12.5%
FY2022Dec 31, 2022$16.77B-7.1%
FY2021Dec 31, 2021$18.05B-3.7%
FY2020Dec 31, 2020$18.75B+3.4%
FY2019Dec 31, 2019$18.14B-7.3%
FY2018Dec 31, 2018$19.57B-29.9%
FY2017Dec 31, 2017$27.92B+26.9%
FY2016Dec 31, 2016$22.01B+144.5%
FY2015Dec 31, 2015$9.00B+15.0%
FY2014Dec 31, 2014$7.83B+19.3%
FY2013Dec 31, 2013$6.56B-68.0%
FY2012Dec 31, 2012$20.48B+32.8%
FY2011Dec 31, 2011$15.41B-18.5%
FY2010Dec 31, 2010$18.92B+15.0%
FY2009Dec 31, 2009$16.46B+43.8%
FY2008Dec 31, 2008$11.45B-6.3%
FY2007Dec 31, 2007$12.21B–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$32.61B+142.7%
Q1 FY2026Mar 31, 2026$34.05B+157.1%
Q4 FY2025Dec 31, 2025$12.93B-8.5%
Q3 FY2025Sep 30, 2025$12.94B-13.6%
Q2 FY2025Jun 30, 2025$13.44B-8.9%
Q1 FY2025Mar 31, 2025$13.24B-9.2%
Q4 FY2024Dec 31, 2024$14.13B-3.8%
Q3 FY2024Sep 30, 2024$14.98B-3.5%
Q2 FY2024Jun 30, 2024$14.75B-12.4%
Q1 FY2024Mar 31, 2024$14.59B-13.7%
Q4 FY2023Dec 31, 2023$14.68B-12.5%
Q3 FY2023Sep 30, 2023$15.53B-5.4%
Q2 FY2023Jun 30, 2023$16.85B+0.5%
Q1 FY2023Mar 31, 2023$16.90B-1.1%
Q4 FY2022Dec 31, 2022$16.77B-7.1%
Q3 FY2022Sep 30, 2022$16.41B-10.8%
Q2 FY2022Jun 30, 2022$16.76B-9.4%
Q1 FY2022Mar 31, 2022$17.09B-7.3%
Q4 FY2021Dec 31, 2021$18.05B-3.7%
Q3 FY2021Sep 30, 2021$18.40B-0.9%
Q2 FY2021Jun 30, 2021$18.50B-6.0%
Q1 FY2021Mar 31, 2021$18.44B+0.9%
Q4 FY2020Dec 31, 2020$18.75B+3.4%
Q3 FY2020Sep 30, 2020$18.56B-2.8%
Q2 FY2020Jun 30, 2020$19.68B+2.5%
Q1 FY2020Mar 31, 2020$18.27B-4.1%
Q4 FY2019Dec 31, 2019$18.14B-7.3%
Q3 FY2019Sep 30, 2019$19.10B-18.9%
Q2 FY2019Jun 30, 2019$19.19B-7.1%
Q1 FY2019Mar 31, 2019$19.05B-13.0%
Q4 FY2018Dec 31, 2018$19.57B-29.9%
Q3 FY2018Sep 30, 2018$23.56B-1.9%
Q2 FY2018Jun 30, 2018$20.67B-14.0%
Q1 FY2018Mar 31, 2018$21.89B-8.7%
Q4 FY2017Dec 31, 2017$27.92B+26.9%
Q3 FY2017Sep 30, 2017$24.03B+182.3%
Q2 FY2017Jun 30, 2017$24.03B–
Q1 FY2017Mar 31, 2017$23.97B–
Q4 FY2016Dec 31, 2016$22.01B–
Q3 FY2016Sep 30, 2016$8.51B–

More Abbott Laboratories figures

See a number that looks wrong?